bisbenzimidazole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Hu, S | 1 |
| Chen, Y | 1 |
| Zhang, X | 1 |
| Gao, H | 1 |
| Tian, J | 1 |
| Chen, J | 1 |
| Patil, R | 1 |
| Kulshrestha, A | 1 |
| Tikoo, A | 1 |
| Fleetwood, S | 1 |
| Katara, G | 1 |
| Kolli, B | 1 |
| Seibel, W | 1 |
| Gilman-Sachs, A | 1 |
| Patil, SA | 1 |
| Beaman, KD | 1 |
2 other studies available for bisbenzimidazole and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Topics: Bisbenzimidazole; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Humans; Phos | 2023 |
Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H⁺)-ATPase Inhibitors.
Topics: Antineoplastic Agents; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug S | 2017 |